Deal watch : BMS acquires rights for IL-6 inhibitor.
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D000093242:Interleukin-6 Inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000093242:Interleukin-6 Inhibitors; C546400:ALD518 monoclonal antibody